The Chemistry Resource Laboratory is an integral part of Roswell Park's drug development program. This resource provides chemistry services (professional advice, technical assistance, chemical syntheses) to the Institute staff members in support of their efforts to develop new anti- cancer therapies and compounds for use in studies related to mode(s) of action of cancer drug(s), biotransformation, drug disposition, etc. The """"""""added value"""""""" of this resource is the unique expertise and state-of-the-art equipment that it provides to deal with all aspects of medicinal chemistry, including the synthesis of a wide and diverse array of compounds such as anti-folates, nucleotides/nucleotide, membrane-active carbohydrates, amino acid analogues, polyamines, anti-sense agents (oligomer-dye complex) porphyrins, modified monomers for modified biopolymer syntheses and reference metabolites. The functions of this CCSG shared resource are: 1) to synthesize potential anti-cancer agents, e.g., in 5-200 g quantities for extensive preclinical chemotherapy; toxicological and pharmacological studies; 2) to prepare key intermediates in 20 g-Kg quantities for the synthesis of potential anti-cancer agents by research chemists at RPCI; 3) to prepare radioactive compounds (3H and 14C labeled) for mechanism of action and drug disposition studies: 4) to synthesize reference metabolites of active compounds for characterization purposes; and 5) to synthesize individual special compounds that demonstrate interesting and/or novel biological activities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016056-26
Application #
6452244
Study Section
Project Start
2001-05-07
Project End
2003-04-30
Budget Start
Budget End
Support Year
26
Fiscal Year
2001
Total Cost
Indirect Cost
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Lu, Yingchang; Beeghly-Fadiel, Alicia; Wu, Lang et al. (2018) A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Res 78:5419-5430
Terakawa, Tomoaki; Katsuta, Eriko; Yan, Li et al. (2018) High expression of SLCO2B1 is associated with prostate cancer recurrence after radical prostatectomy. Oncotarget 9:14207-14218
Zhu, Qianqian; Yan, Li; Liu, Qian et al. (2018) Exome chip analyses identify genes affecting mortality after HLA-matched unrelated-donor blood and marrow transplantation. Blood 131:2490-2499
Visioni, Anthony; Kim, Minhyung; Wilfong, Chandler et al. (2018) Intra-arterial Versus Intravenous Adoptive Cell Therapy in a Mouse Tumor Model. J Immunother 41:313-318
Li, Yanchun; Opyrchal, Mateusz; Yao, Song et al. (2018) The role of programmed death ligand-1 and tumor-infiltrating lymphocytes in breast cancer overexpressing HER2 gene. Breast Cancer Res Treat 170:293-302
Mastri, Michalis; Lee, Christina R; Tracz, Amanda et al. (2018) Tumor-Independent Host Secretomes Induced By Angiogenesis and Immune-Checkpoint Inhibitors. Mol Cancer Ther 17:1602-1612
Dong, Jing; Levine, David M; Buas, Matthew F et al. (2018) Interactions Between Genetic Variants and Environmental Factors Affect Risk of Esophageal Adenocarcinoma and Barrett's Esophagus. Clin Gastroenterol Hepatol 16:1598-1606.e4
Sass, Stephanie N; Ramsey, Kimberley D; Egan, Shawn M et al. (2018) Tumor-associated myeloid cells promote tumorigenesis of non-tumorigenic human and murine prostatic epithelial cell lines. Cancer Immunol Immunother 67:873-883
Neubauer, Bjoern; Schrankl, Julia; Steppan, Dominik et al. (2018) Angiotensin II Short-Loop Feedback: Is There a Role of Ang II for the Regulation of the Renin System In Vivo? Hypertension 71:1075-1082
Goodrich, Maxwell M; Talhouk, Ramzi; Zhang, Xiaojing et al. (2018) An approach for controlling the timing and order of engineered mutations in mice. Genesis 56:e23243

Showing the most recent 10 out of 1555 publications